Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.

Daniel P. Cahill; Asha George; Mark R. Gilbert; Arnab Chakravarti; Roger Stupp; Monika Hegi; Paul Brown; Kurt A. Jaeckle; Benjamin Corn; Erik P. Sulman; Luis Souhami; Maria Werner-Wasik; Bethany M. Anderson; Minesh Mehta; Kenneth D. Aldape

doi:10.1158/1535-7163.TARG-13-A110

Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.

Daniel P. Cahill, Asha George, Mark R. Gilbert, Arnab Chakravarti, Roger Stupp, Monika Hegi, Paul Brown, Kurt A. Jaeckle, Benjamin Corn, Erik P. Sulman, Luis Souhami, Maria Werner-Wasik, Bethany M. Anderson, Minesh Mehta, Kenneth D. Aldape

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Molecular Cancer Therapeutics
Volume	12
DOIs	https://doi.org/10.1158/1535-7163.TARG-13-A110
State	Published - Nov 1 2013

Disciplines

Biology
Immunology and Infectious Disease

Access to Document

10.1158/1535-7163.TARG-13-A110License: Unspecified

Cite this

Cahill, D. P., George, A., Gilbert, M. R., Chakravarti, A., Stupp, R., Hegi, M., Brown, P., Jaeckle, K. A., Corn, B., Sulman, E. P., Souhami, L., Werner-Wasik, M., Anderson, B. M., Mehta, M., & Aldape, K. D. (2013). Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. Molecular Cancer Therapeutics, 12. https://doi.org/10.1158/1535-7163.TARG-13-A110

Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. / Cahill, Daniel P.; George, Asha; Gilbert, Mark R. et al.
In: Molecular Cancer Therapeutics, Vol. 12, 01.11.2013.

Research output: Contribution to journal › Article › peer-review

Cahill, DP, George, A, Gilbert, MR, Chakravarti, A, Stupp, R, Hegi, M, Brown, P, Jaeckle, KA, Corn, B, Sulman, EP, Souhami, L, Werner-Wasik, M, Anderson, BM, Mehta, M & Aldape, KD 2013, 'Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.', Molecular Cancer Therapeutics, vol. 12. https://doi.org/10.1158/1535-7163.TARG-13-A110

Cahill DP, George A, Gilbert MR, Chakravarti A, Stupp R, Hegi M et al. Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. Molecular Cancer Therapeutics. 2013 Nov 1;12. doi: 10.1158/1535-7163.TARG-13-A110

@article{3ab8fda1fb5044e096dad68183bb3e35,

title = "Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.",

author = "Cahill, \{Daniel P.\} and Asha George and Gilbert, \{Mark R.\} and Arnab Chakravarti and Roger Stupp and Monika Hegi and Paul Brown and Jaeckle, \{Kurt A.\} and Benjamin Corn and Sulman, \{Erik P.\} and Luis Souhami and Maria Werner-Wasik and Anderson, \{Bethany M.\} and Minesh Mehta and Aldape, \{Kenneth D.\}",

note = "Background: Glioblastomas (GBMs) are aggressive primary brain tumors with high levels of genomic heterogeneity impacting prognosis and treatment response. A recurrent in-frame deletion within the extracellular domain of the epidermal growth factor receptor (EGFR variant III, or vIII) is found in a substantial fraction of GBMs. Methods: The Radiation Therapy Oncology Group (RTOG) 0525 trial of temozolomide dosing in newly-diagnosed GBM enrolled 1174 patients.",

year = "2013",

month = nov,

day = "1",

doi = "10.1158/1535-7163.TARG-13-A110",

language = "American English",

volume = "12",

journal = "Molecular Cancer Therapeutics",

}

TY - JOUR

T1 - Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.

AU - Cahill, Daniel P.

AU - George, Asha

AU - Gilbert, Mark R.

AU - Chakravarti, Arnab

AU - Stupp, Roger

AU - Hegi, Monika

AU - Brown, Paul

AU - Jaeckle, Kurt A.

AU - Corn, Benjamin

AU - Sulman, Erik P.

AU - Souhami, Luis

AU - Werner-Wasik, Maria

AU - Anderson, Bethany M.

AU - Mehta, Minesh

AU - Aldape, Kenneth D.

N1 - Background: Glioblastomas (GBMs) are aggressive primary brain tumors with high levels of genomic heterogeneity impacting prognosis and treatment response. A recurrent in-frame deletion within the extracellular domain of the epidermal growth factor receptor (EGFR variant III, or vIII) is found in a substantial fraction of GBMs. Methods: The Radiation Therapy Oncology Group (RTOG) 0525 trial of temozolomide dosing in newly-diagnosed GBM enrolled 1174 patients.

PY - 2013/11/1

Y1 - 2013/11/1

UR - http://mct.aacrjournals.org/content/12/11_Supplement/A110

U2 - 10.1158/1535-7163.TARG-13-A110

DO - 10.1158/1535-7163.TARG-13-A110

M3 - Article

VL - 12

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

ER -

Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.

Disciplines

Access to Document

Other files and links

Cite this